In this episode, Jill Blumenthal, MD, MAS, discusses HIV pre-exposure prophylaxis (PrEP) considerations for transgender and nonbinary individuals, including:Providing gender-affirming careIntegrating PrEP and gender careTaking a sexual history and addressing sexual healthPrEP efficacy and options for transgender individuals, including FTC/TDF, FTC/TAF, and long-acting CABThe importance of reassuring transgender individuals that data suggest there are no drug–drug interactions between gender-affirming hormone therapy and any of the PrEP options Jill Blumenthal, MD, MAS (she/hers)Associate Professor of MedicineInfectious Diseases and Global Public HealthUniversity of California, San DiegoSan Diego, California See the full program at: https://bit.ly/3WhbBvZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related